Advertisement

International Journal of Hematology

, Volume 79, Issue 4, pp 394–399 | Cite as

Significance of Decreased Plasma D-Dimer Levels following Lipopolysaccharide-Induced Disseminated Intravascular Coagulation in Rats

  • Hidesaku Asakura
  • Yoko Sano
  • Mika Omote
  • Tomotaka Yoshida
  • Yasuo Ontachi
  • Tomoe Mizutani
  • Minori Kaneda
  • Masahide Yamazaki
  • Eriko Morishita
  • Akiyoshi Takami
  • Ken-ichi Miyamoto
  • Shinji Nakao
Article

Abstract

Plasma D-dimer (DD) is considered to be one of the most useful markers in the diagnosis and assessment of disseminated intravascular coagulation (DIC). The present study was performed to clarify the role of DD in a rat model of lipopolysac-charide (LPS)-induced DIC in which low—molecular-weight heparin (LMWH) and tranexamic acid (TA) were used. We investigated whether a relationship exists between plasma DD levels and severity of DIC. Experimental DIC was induced in rats by a sustained 4-hour infusion of 30 mg/kg LPS administered via the tail vein (LPS group). Rats received either LPS alone (LPS group) or LPS combined with 200 U/kg LMWH (LPS+LMWH group) or 50 mg/kg TA (LPS+TA group) from-30 minutes to 4 hours. Blood was drawn from each rat at 4, 8, and 12 hours. Plasma levels of thrombin-antithrombin complex (TAT) and creatinine were suppressed in the LPS+LMWH group, and less glomerular fibrin deposition was observed compared with the LPS group. On the other hand, an increased level of creatinine and increased glomerular fibrin deposition were observed in the LPS+TA group compared with the LPS group. LMWH demonstrated a protective effect against LPS-induced DIC, resulting in increased survival at 12 hours, whereas TA had the opposite effect. From these results, it appears that LMWH protects against LPS-induced DIC, but TA exacerbates LPS-induced DIC. It was interesting that plasma levels of DD were almost completely suppressed by concurrent administration of either TA or LMWH in this LPS-induced DIC model. This finding suggested that plasma levels of DD were suppressed by inhibition of coagulation (reduced deposition of fibrin) in the LPS+LMWH group and that DD levels were also suppressed by inhibition of fibrinolysis (reduced degradation of fibrin by plasmin) in the LPS+TA group. Thus care should be taken when evaluating the significance of plasma DD levels, because suppressed levels can occur with progressive fibrin deposition and worsening organ dysfunction or improvement in the course of DIC.

Key words

DIC Lipopolysaccharide D-dimer Tranexamic acid Low-molecular-weight heparin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Levi M, Ten Cate H. Disseminated intravascular coagulation.N Engl J Med. 1999;341:586–592.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations.Semin Thromb Hemost. 1998; 24:3–18.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Okajima K. Regulation of inflammatory responses by natural anticoagulants.Immunol Rev. 2001;184:258–274.CrossRefGoogle Scholar
  4. 4.
    Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases.Am J Hematol. 2000;65:215–222.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Asakura H, Jokaji H, Saito M, et al. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers.Blood Coagul Fibrinolysis. 1994;5:829–832.CrossRefGoogle Scholar
  6. 6.
    Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia.Br J Haematol. 1988;70:43–48.CrossRefGoogle Scholar
  7. 7.
    Wada H, Kumeda Y, Ogasawara Z, et al. Plasminogen activators and their inhibitors in leukemic cell homogenates.Am J Hematol. 1993;42:166–170.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Paramo JA, Fernandez Diaz FJ, Rocha E. Plasminogen activator inhibitor activity in bacterial infection.Thromb Haemost. 1988;59:451–454.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Wada H, Yamamuro M, Inoue A, et al. Comparison of the responses of global tests of coagulation with molecular markers of neutrophil, endothelial, and hemostatic system perturbation in the baboon model ofE. coli sepsis: toward a distinction between uncompensated overt DIC and compensated non-overt DIC.Thromb Haemost. 2001;86:1489–1494.CrossRefPubMedGoogle Scholar
  10. 10.
    Asakura H, Suga Y, Aoshima K, et al. Marked difference in patho-physiology between tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats.Crit Care Med. 2002;30:161–164.CrossRefPubMedGoogle Scholar
  11. 11.
    Asakura H, Suga Y, Yoshida T, et al. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats.Blood Coagul Fibrinolysis. 2003;14:221–228.PubMedGoogle Scholar
  12. 12.
    Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan.Bibl Haematol. 1983;49:265–275.Google Scholar
  13. 13.
    Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response.Semin Thromb Hemost. 1996;22:69–88.CrossRefPubMedGoogle Scholar
  14. 14.
    Matsuda T. Clinical aspects of DIC-disseminated intravascular coagulation.Pol J Pharmacol. 1996;48:73–75.PubMedGoogle Scholar
  15. 15.
    Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.Thromb Haemost. 2001;86:1327–1330.CrossRefPubMedGoogle Scholar
  16. 16.
    Asakura H, Okudaira M, Yoshida T, et al. Induction of vasoactive substances differs in LPS-induced and TF-induced DIC models in rats.Thromb Haemost. 2002;88:663–667.CrossRefPubMedGoogle Scholar
  17. 17.
    Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay.Thromb Haemost. 1988;59:101–106.CrossRefGoogle Scholar
  18. 18.
    Yamazaki M, Asakura H, Aoshima K, et al. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.Semin Thromb Hemost. 1996;22:255–259.CrossRefPubMedGoogle Scholar
  19. 19.
    Ferreia HC, Murat LG. Immunological method for demonstrating fibrin degradation products in serum and its use in the diagnosis of fibrinolytic states.Br J Haematol. 1963;9:299–310.CrossRefGoogle Scholar
  20. 20.
    Kawasaki H, Hayashi K, Awai M. Disseminated intravascular coagulation (DIC): immunohistochemical study of fibrin-related materials (FRMs) in renal tissues.Acta Pathol Jpn. 1987;37:77–84.PubMedGoogle Scholar
  21. 21.
    Whitaker AN, Elms MJ, Masci PP, et al. Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies.J Clin Pathol. 1984;37:882–887.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Carr JM, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation: role of D-dimer.Am J Clin Pathol. 1989; 91:280–287.CrossRefPubMedGoogle Scholar
  23. 23.
    Bick RL, Baker WF. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC).Thromb Res. 1992; 65:785–790.CrossRefPubMedGoogle Scholar
  24. 24.
    Del Principe D, Cesareo R, Tallarida BM, Ciancarelli MG, Ricci M, Mancuso G. Labelling of blood platelets with stable tracers.Thromb Haemost. 1980;44:30–31.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Hidesaku Asakura
    • 1
  • Yoko Sano
    • 2
  • Mika Omote
    • 3
  • Tomotaka Yoshida
    • 3
  • Yasuo Ontachi
    • 1
  • Tomoe Mizutani
    • 1
  • Minori Kaneda
    • 1
  • Masahide Yamazaki
    • 1
  • Eriko Morishita
    • 1
  • Akiyoshi Takami
    • 1
  • Ken-ichi Miyamoto
    • 2
  • Shinji Nakao
    • 1
  1. 1.Department of Internal Medicine (III)Kanazawa University School of MedicineIshikawaJapan
  2. 2.Hospital PharmacyKanazawa University School of MedicineKanazawaJapan
  3. 3.Department of Laboratory MedicineKanazawa University School of MedicineKanazawaJapan

Personalised recommendations